PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy

Key Points

• Overall survival rates increased with consolidation durvalumab in unresectable stage III NSCLC, and no progression was noted post-chemoradiotherapy.
• The treatment explored the impact of durvalumab on patients who did not progress after receiving chemoradiotherapy.
• Phase III clinical trial analyzed the efficacy of durvalumab as a consolidation therapy for NSCLC.
• The findings may highlight the potential for improved patient management in advanced lung cancer cases.